The Impact of Tardive Dyskinesia: The Data and a Patient Story

PROGRAM INFORMATION
Friday, June 23, 2023
11:45 am–1:00 pm CT
Room La Nouvelle AB
Ernest N. Morial Convention Center
New Orleans, LA
Lunch will be provided by AANP

PRESENTED BY
Kevin Williams, MS, MPAS, PA-C
Owner and Lead Clinician
Department of Psychiatry
OnPoint Behavioral Health Inc.
Adjunct Professor
Department of Physician Assistant Studies
University of Tampa
Tampa, FL

Patient Ambassador
Davitria

PROGRAM OBJECTIVES
• Communicate the burden and impact of tardive dyskinesia (TD)
• Review a patient’s experience with TD and the impact it has had on their mental well-being
• Discuss an FDA-approved treatment for adults with TD

The speakers are presenting on behalf of and are paid consultants for Neurocrine Biosciences.

Important Information
INDICATION & USAGE
INGREZZA® (valbenazine) capsules is indicated for the treatment of adults with tardive dyskinesia.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.

WARNINGS & PRECAUTIONS
Sommolence
INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.

QT Prolongation
INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.

WARNINGS & PRECAUTIONS (continued)
Parkinsonism
INGREZZA may cause parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.

ADVERSE REACTIONS
The most common adverse reaction (>5% and twice the rate of placebo) is somnolence. Other adverse reactions (>2% and >Placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see adjacent page for INGREZZA Brief Summary of Prescribing Information or visit https://www.neurocrine.com/ingrezzapi for full Prescribing Information.